RV3-BB Rotavirus Vaccine Phase IIb Clinical Trial of efficacy, safety and immunogenicity
A Phase IIb, double-blind, randomised, placebo-controlled parallel group study of the efficacy, safety and immunogenicity of oral RV3-BB Rotavirus Vaccine, administered as a neonatal schedule with birth (age 0-5 days) dose, 8-10 and 14-16 week doses or an infant schedule of 8-10 ,14-16 and 18-20 week doses.
Murdoch Children's Research Institute (MCRI)
1,647 participants
Jan 18, 2013
Interventional
Conditions
Summary
A phase I clinical trial completed in Melbourne in 2011 found the RV3-BB vaccine to be well-tolerated in adults, children and babies 6-8 weeks of age (ACTRN12610000525088). A phase IIa clinical trial in Dunedin (ACTRN12611001212943) was designed to assess immunogenicity of the vaccine. The aim of this phase IIb trial is to determine the efficacy of the vaccine. Newborn babies are included in this trial to examine whether administering this vaccine at birth will offer the earliest and possibly greatest protection. Each of the babies will be randomly assigned to groups, so that two thirds of the babies will receive 3 doses of oral RV3 vaccine and one third of the babies will receive oral doses of placebo. In total each baby’s involvement will include monthly visits and additional regular follow up until 18 months of age.
Eligibility
Inclusion Criteria1
- Healthy full-term baby 0 - 5 days of age.
Exclusion Criteria2
- Major congenital malformations or genetically determined disease, intussusception,
- immune system disease, prior receipt of (or exposure in utero to) immunosuppressive therapy, cytotoxic or hepatotoxic drugs, bleeding diathesis, significant evolving neurological disorder, previous anaphylactic reaction, contraindication of EPI vaccines or components, receipt of any other rotavirus vaccine, vomiting, diarrhoea or fever in 24 hours prior to first dose.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RV3-BB rotavirus vaccine is 1ml sterile cell-free aqueous solution for oral administration, containing RV3-BB live naturally attenuated human rotavirus particles (at a concentration of 8.3E6 FFU/ml), in cell culture medium containing 10% sucrose. All participants will receive 4 doses of investigatonal product, at birth (0-5 days), 8-10 weeks, 14-16 weeks and 18-20 weeks of age. - The neonatal schedule arm will receive active Investigational Product for the 1st, 2nd and 3rd doses and placebo for the 4th dose - The infant schedule arm will receive placebo for the 1st dose and active Investigational Product for the 2nd, 3rd and 4th doses - The placebo schedule arm will receve placebo for all 4 doses.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001282875